CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. (Nasdaq: CNTG) today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT…

Read more

CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to…

Read more

CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, November 14, 2023 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), the essential life science…

Read more

CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering

Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology

Read more

CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, September 11, 2023 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), the essential life science…

Read more

CENTOGENE Reports First Half 2023 Financial Results

Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance

Read more

CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients

CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,…

Read more

CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative…

Read more

CENTOGENE to Participate in Upcoming Conferences in August

CENTOGENE representatives are attending events in Brazil and Switzerland, and will be available to discuss Pharma, CRO, and Diagnostic collaboration…

Read more

CENTOGENE Regains Compliance With Nasdaq Listing Requirements

Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,…

Read more

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads